PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer
PROMISE Registry on Standardized Evaluation of PSMA-PET and Outcome in Prostate Cancer
University Hospital, Essen
10,000 participants
Mar 5, 2024
OBSERVATIONAL
Conditions
Summary
Background: PROMISE criteria have been defined for standardized reporting of Prostate-Specific Membrane Antigen (PSMA) PET whole-body stage of prostate cancer. PSMA PET disease extent by PROMISE has been associated with oncologic outcome. Need: Improved prognostication across various stages of prostate cancer is needed for management guidance and study design. Aim: 1. To assess the prognostic value of PSMA PET 2. To compare the prognostic value of PSMA PET with clinical prognostic scores in patients with prostate cancer at various disease stages Inclusion: * Adult patients with * biopsy/histo proven prostate cancer who * underwent PSMA PET (any type) * for staging or re-staging at any stage and who * have at least 3-year overall survival follow-up data available will be included consecutively. Exclusion: * Patients with neuroendocrine prostate cancer * Patients with metastasized or disseminated malignancy other than prostate cancer
Eligibility
Inclusion Criteria5
- Adult patients with
- biopsy/histo proven prostate cancer who
- underwent PSMA PET (any type)
- for staging or re-staging at any stage and who
- have at least 3-year overall survival follow-up data available will be included consecutively.
Exclusion Criteria2
- Patients with neuroendocrine prostate cancer
- Patients with metastasized or disseminated malignancy other than prostate cancer.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06320223